Search

Search results

Light sensing small molecule given green light

Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.

Retina UK awards new research funding

Retina UK is delighted to have awarded a new three-year research grant to Prof Majlinda Lako at Newcastle University for a project entitled: To establish AAV.PRPF31 gene augmentation in PRPF31-deficient RPE and photoreceptor cells and assess its efficacy in restoring RPE and photoreceptor function.

Jing Yu - a man wearing an orange t shirt facing the camera. There is a microscope to his left on a desk.

A blog from the research coal face

Jing Yu is a bioinformatician with the Eye Research Group at Oxford University, and is part of the UK Inherited Retinal Dystrophy Consortium (UKIRDC) team, funded by a Retina UK  grant.

Our commitment to lived experience employment

In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our sector, including at senior management level.

A megaphone with the words 'make your voice heard. Complete the Retina UK sight loss survey'

Help to shape our future

Would you like to help shape Retina UK’s future? Do you want to ensure decision-makers understand the impact of inherited sight loss? If so we’d love to hear from you.